one-hit wonder initi
pipelin product lead product target
cytokin implic multipl atop indic demonstr
promis efficaci poc studi atop dermat readout
eosinophil asthma studi could elev asset potenti
bolster investor confid approach biolog atop
dermat asthma grow class competit evolv
landscap expert indic ampl room differenti exist
remain high unmet need indic togeth believ
two indic repres peak sale opportun
size single-dos limit direct compar versu
biolog expert independ indic mechan attract
improv vs placebo in-lin manag
guidanc would creat optim long term competit asthma
exacerb reduct futur studi assum po
program tp valu asthma see upside/downsid
target price event
busi year ahead keep interest high besid asthma
readout phase data atop dermat expect
offer earli insight potenti differenti competitor final poc
data two form orphan psoriasi gpp
possibl end ppp expect could offer anoth valu
creation path current model peak sale
valuationiniti coverag outperform rate
tp valuat base blend dcf project risk
thesi includ failur clinic trial commerci regulatori
headwind also note limit clinic efficaci data exist date
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani develop first-in-class
antibodi product candid focus unmet medic need
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
within next mo posit readout across multipl
program increas po asthma atop
dermat gpp/ppp higher
peak share atop dermat
failur across asthma gpp/ppp io partner program po
lower convict atop dermat data
po reduc pipelin valu
 close
initi coverag outperform rate target
develop lead wholli own antibodi program sever inflammatori
indic complet initi efficaci studi atop dermat
peanut allergi readout eosinophil asthma studi could
derisk asset increas investor confid potenti broad util
product across sever atop indic second wholli own asset
explor two form orphan psoriasi see
stock under-perform vs nbi follow peanut allergi
data march think reflect greater investor caution expect
perhap overdon follow posit phase atop dermat data also
recognit develop path highli promis go take
sever year play
believ promis data atop dermat addit
potenti faster develop path gpp ppp set base build
share go forward asthma data potenti rapidli restor
investor enthusiasm anab approach atop diseas see substanti
upsid potenti addit indic discoveri platform
compani cash equival expect last
could receiv addit non-dilut capit partnership tesaro
key catalyst stock remaind year manag target
improv placebo follow singl dose posit
outcom increas investor confid approach potenti broad
util potenti upsid valuat tp
includ asthma assign po program reflect risk
trial
credit suiss biotech long-term outlook develop larg
competit market expect share trade function investor percept
total address market competit posit across evolv
develop landscap better visibl commerci opportun peanut allergi
atop indic phase readout also potenti sourc
upsid longer term
credit suiss biotech outlook brought sever program
clinic year indic substanti potenti antibodi discoveri
platform believ attract long-term target given potenti
differenti clinic asset larg market along consider drug discoveri valu
potenti acquir also develop drug candid indic
sever explor target gsk azn
current market leader first-mov class like emerg
attract target larger phase dataset confirm expand result earli
asthma readout
substanti genet evid support
approach asthma eosinophil reduct ad trial
bode well trial could establish differenti
profil biolog landscap
asthma competit crowd multipl
agent promis efficaci difficult
differenti asthma readout gambl anyth less
dupix wont commerci viabl
asthma readout like provid earli efficaci sign though wont compar basi dupix way
given particular single-dos design isnt perfect correl across blood eosinophil reduct
improv exacerb rate rough direct relationship across endpoint demonstr multipl
asthma trial believ enough evid warrant explor indic though acknowledg substanti
unknown limit cross-trial interpret see upside/downsid target price event
ii atop dermat
show dupi-lik efficaci single-dos studi
improv multipl dose dose regimen
competit dupi oral jaki get broad
uptak popul given alreadi increas risk
infect black-box warn
studi patient imposs
conclud anyth patient physician alway
prefer oral agent even approv indic
compet small biolog share
believ well posit atop dermat though note small sampl size evolv competit landscap
earli data promis consult indic expect efficaci potenti increas multipl dose less-
frequent dose dupix like go competit especi consid biolog fail
indic skeptic argument broad adopt oral jaki indic final note dupix
agent increas patient awar grow market multibillion dollar opportun believ
pipelin technolog platform
anab discoveri platform could offer substanti upsid
stock compani taken clinic sever promis asset
best-in-class potenti gpp/ppp could
opportun partnership tesaro celgen may
offer substanti non-dilut capit royalti
compani tri develop asset indic
competit single-dos exploratori studi difficult
interpret compar limit valu assign
indic long develop path
asthma ad isnt enough evid warrant high
convict partner io asset
discoveri platform extrem product led promis clinic asset overal like
compani select approach product develop inflamm instead pursu oncolog even competit
dermatolog indic though agre single-dos studi affect interpret see strategi
capital-effici way develop asset pipeline-in-a-product potenti
ppp phase initi
first-in-class asset potenti
broad applic
anab approach strong scientif rational treatment multipl
atop diseas demonstr promis poc data atop dermat
sign efficaci peanut allergi asthma readout next key catalyst
potenti compet larg competit market though expert
highlight remain unmet need allerg indic anab
approach among promis target develop
antibodi target link sever atop
diseas act upstream tradit target inflamm pathway
target could broad applic atop diseas
current develop atop dermat asthma peanut
allergi potenti addit indic road
figur upstream cytokin involv atop diseas
phase studi agent found dose-limit toxic singl
ascend dose pharmacodynam effect observ singl dose
day dose importantli signific differ serum
exposur termin half-lif day iv sc deliveri level
promis poc data atop dermat
atop dermat ad chronic inflammatori skin diseas may lead skin
dryness erythema ooz crust lichenif ad typic accompani
pruritu itch substanti impact patient qualiti life owe
time-intens skin-car routin poor qualiti sleep visual sign diseas
standard care involv topic corticosteroid emolli patient
moderate-to-sever diseas frequent flare need immunosuppress
adult
moder
topic agent
uncontrol topic
atop dermat competit field multipl agent current develop
recent approv sny/regn dupix atop dermat rais efficaci
bar indic think opportun differenti still exist
figur multipl target explor atop dermat
phase ii start
phase iib start
phase start
credit suiss estim oral agent adapt renert-yuv yael emma guttman-yasski system therapi atop
dermat pipelin clinic dermatolog
pk/pd properti strong poc suggest potenti
conduct small single-dos studi moderate-to-sever adult atop
dermat ad subject subject dose placebo follow singl
dose
subject inadequ control topic corticosteroid seven subject
previous treat system therapi present baselin eczema
area sever index easi score remain five present
baselin easi score overal baselin easi
charl martineau univers toronto figur baselin characterist in-lin ad studi
subject receiv singl dose iv placebo day follow singl dose mg
iv day efficaci endpoint easi index measur throughout studi
overal feedback expert indic efficaci result promis though
small sampl
rel baselin upon enrol day
efficaci seen earli day peak activ day
evidenc subject achiev reduct easi score
day subject achiev reduct easi score
day notabl efficaci sustain prolong period time think
dose regimen possibl similar efficaci seen regardless
diseas sever baselin consult expect data improv futur multi-
expert see data roughli equival earli clinic data dupix
though highlight small sampl size refer initi phase four-week
studi dupix demonstr overal subject dose
combin subject receiv weekli sc weekli
cohort subject achiev
compani data credit suiss dupix efficaci data dose level
well toler concern drug-rel safeti signal observ
headach observ subject
base result phase studi initi phase
placebo-control studi moderate-to-sever atop dermat
studi start date may accord clinicaltri gov compani explor
differ dose interv subcutan dose though detail
disclos data expect primari complet date june accord
clinicaltri gov repres anoth key inflect point stock
primari efficaci endpoint studi percent chang easi score week
competit landscap current focu dupix oral jaki
dupix administ sc first biolog approv moderate-
to-sever atop dermat consult indic dupix current go-to
option moderate-to-sever patient owe strong efficaci manag
safeti profil note conjunct observ patient treat
dupix clinic trial though major concern clinician
weve spoken
advanc develop clinician like compar result
dupix summari dupix clinic efficaci atop dermat follow
score
score
iga score
chang iga score
baselin
chang easi score
baselin
iga score
iga score
oral jak inhibitor demonstr promis earli efficaci data ad oral
dose could signific competit advantag patient accord
consult howev unclear overal safeti profil jaki
associ increas risk infect compar agent approv
develop expert express potenti reduc complianc oral
therapeut compar biolog
number patient
easi score week
easi score week
easi week
easi week
iga week
pruritus/itch week
week
week
number patient
iga week
easi score week
iga week
easi score week
atop dermat expert feedback target product profil
allergist dermatologist spoke emphas follow characterist
product develop atop dermat
monthli dose regimen seen ideal complianc would easier
patient rememb includ schedul
biolog subcutan self-inject would
ideal rout
administr would expect iv drug limit appeal especi
consid dupix dose sc home
oral agent could attract option mani patient util oral
agent biolog individu choic case anecdot
consult indic patient take biolog gener compliant
one take oral sever indic psoriasi often-cit
exampl trade-off long-act biolog versu daili oral could
favor biolog assumpt compar efficacy/safeti profil otherwis
physician patient assign highest import quality-of-lif endpoint
practic substanti reduct pruritu get patient iga visual
overal evalu ad lesion sever scale clear sever seen
relev overal reduct easi
safeti profil agent benign patient could alreadi
increas risk infect ad lesion
limit option current avail physician acknowledg
patient may eventu cycl multipl agent optim profil diseas
manag found case payor-impos restrict may also play role
direct patient specif product though earli assess impact ad
potenti differenti market assumpt
believ multipl potenti path differenti ad
expert feedback suggest potenti sc could substanti
despit earli data small sampl size limit efficaci analysi
potenti differenti efficaci multipl dose may yield
revenu build base case make follow assumpt
market entri us eu
phase initi expect data phase could start
early/mid commerci launch earli
price compar dupix per year gross
compani suggest possibl partner ex-u
consid compani self-commerci product model purpos
ad adult preval thousand
moder sever ad
moder sever
uncontrol topic
yr
asthma poc readout nt driver
target mechan action consid promis consult
target cytokin upstream cytokin involv asthma il-
genet studi demonstr clear linkag sever
asthma propos sc administr like attract rel
exist option space initi efficaci data begin defin
potenti competit posit sever asthma
sever biolog current approv develop treatment
sever asthma xolair anti-ig antibodi approv enjoy
success among patient high ige level among feedback
consult suggest limit util cinqair sinc iv infus studi
sc formul recent fail major new start direct nucala
sc dose fasenra sc dose
physician spoke gener believ agent roughli equival
efficaci perspect head-to-head trial compar agent
patient well manag
nucala/fasenra abl get diseas control cinqair
physician construct potenti approv antibodi dupix
asthma pdufa date octob expert consid
better efficaci rel dose frequenc could drawback dose
regimen dupix sc vs fasenra product self-administ
home patient atop dermat could signific differenti factor
versu current approv biolog asthma current requir dose
healthcar facil
among product current clinic develop expert discuss yield high
enthusiasm tezepelumab az/amgn monoclon antibodi bind
tslp anoth cytokin act upstream target current approv agent
good even better dupix signific reduct exacerb rate
regardless blood eosinophil count enrol potenti dose
mention
charl martineau univers toronto figur approv biolog clinic pipelin asthma
reduct
black box risk anaphylaxi administ
hc set prepar manag anaphylaxi
observ patient appropri period
time administr
black box risk anaphylaxi administ
hc set healthcar profession
prepar manag anaphylaxi teva
announc failur sc formul
ciqair
reconstitut administ healthcar
profession monitor patient
administr biolog agent
administ hc profession
monitor patient administr
biolog agent recommend
pivot trial demonstr reduct overal popul
reduct high eosinophil popul eos/ml
 reduct among differ dose cohort similar result
observ patient regardless blood eosinophil count enrol
primari endpoint particip
on-going eosinophil high subject
trial show reduct low dose high dose
biomark high trial show reduct biomark high
imbal incid herp zoster
program suspend
trial show reduct stat-sig all-com popul
feno-high particip trial feno-high subject show
reduct stat-sig
program suspend
termin futil
frame expect phase top-lin readout
consult indic strong scientif rational target asthma
gener optimist prospect indic
link eosinophil activ inflamm
clear genet link asthma valid approach
loss function mutat lower risk asthma
loss inhibitor increas risk asthma
target may prevent compens cytokin could potenti
address broad popul also promis option patient
inflammation-driven co-morbid atop dermat food allergi
improv gener observ earli therapi expert indic
increas placebo competit efficaci extrapol comparison
may somewhat limit clear comp single-dos studi
conduct placebo-control trial adult sever eosinophil
asthma random singl dose placebo efficaci endpoint
includ forc expiratori volum second chang blood eosinophil
count believ appropri endpoint given single-dos short
durat trial
direct indic chang blood eosinophil level exhibit
variabl depend moa previou asthma trial exampl biolog
asthma decreas blood eosinophil count transient increas blood
eosinophil case eosinophilia observ dupix asthma trial
improv gener observ shortli first dose
success biolog clinic trial believ like compani abl
demonstr efficaci sign single-dos studi howev though gener
direct align examin histor asthma studi direct
correl magnitud improv degre reduct
exacerb rate typic primari endpoint substanti variabl
improv placebo across variou biolog success develop
dupix variou
therapi demonstr rang
improv shorter- long-term studi dont see lot valu
cross-comparison owe differ studi upcom single-
produc absolut improv vs placebo rang
week meanwhil dupix demonstr improv
placebo overal popul approv dose
studi endpoint improv close high baselin
eosinophil subgroup efficaci seen soon week increas time
remain roughli within narrow rang week
consid single-dos natur anab trial caveat cross-trial
comparison especi consid small sampl size believ delta
versu placebo would suggest program likelihood long-term
success enough warrant explor improv
versu placebo would consid highli promis clinician spoke
absolut term expert express us improv versu
placebo would regard encourag make caveat small
sampl size studi make result somewhat inconclus pend studi
ultim long-term studi repeat dose possibl futur phase
studi evalu addit reduct clinic exacerb need
fulli defin product competit posit sever asthma
total number particip
mean chang baselin week
mean chang baselin week
total number particip
mean chang baselin week
mean chang baselin week
total number particip
mean chang baselin week
mean chang baselin week
total number particip
mean chang baselin week
mean chang baselin week
total number particip
mean chang baselin week
mid eo cell
total number particip
mean chang baselin week
total number particip
mean chang baselin week
mean chang baselin week
estim mean chang baselin week
charl martineau univers toronto figur improv estim current approv agent
ml
minim mix effect prebronchodil improv vs placebo
asthma expert feedback product profil
consult indic despit avail mani option among biolog
treatment asthma unmet need still remain patient respond current
treatment biolog util still earli inning
among characterist biolog indic consult highlight
efficaci perspect consult indic two potenti profil
establish high efficaci subset popul clearli
identifi easy-to-measur biomark
establish efficaci regardless biomark remain unmet need
low eosinophil/ig patient
magnitud exacerb reduct could still differenti factor
compel threshold versu agent
onset action may play import role complianc would serv
posit reinforc patient
might difficult differenti dose regimen alon sinc sc
option avail dupix dose frequent approv
biolog asthma approv self-inject atop dermat
could appeal patient
current approv biolog label dose healthcar facil
consult consid risk anaphylaxi clinic practic low xolair
cinqair black box warn risk anaphylaxi fasenra nucala
warn cite complianc follow-up main driver
patient come biolog administr unclear dupix
potenti label self-inject home would disrupt clinic practic forc
exist player explor develop self-inject version drug
larg address market grow class
estim million adult patient diagnos asthma
us roughli adult sever asthma insuffici control
standard-of-car estim roughli in-lin expert feedback though
actual address popul may difficult assess expert highlight
corticosteroid spar effect biolog interest could drive broader
adopt depend reimburs price
estim asthma biolog sale approach grow
next year opportun expert indic us
expect plenti growth market biolog current wide util
addit market entrant lead higher awar believ potenti
differenti profil class note uncertainti evolv landscap
high competit indic
preval adult
sever
ic laba
adult asthma preval sever persist asthma uncontrol ic laba
posit phase studi result would warrant explor asthma
strengthen anab argument approach could broad therapeut
activ sever atop indic
futur phase phase studi could take time complet potenti
launch label expans sever asthma potenti occur
product develop along similar timelin biolog space
current build assumpt placehold peak market share among biolog
sever asthma assum po reflect establish
mechan action ad single-dos safeti off-set lack clinic data
asthma indic target price incorpor approxim valu
asthma clinic result asthma like result meaning adjust
assumpt
sever asthma uncontrol ic laba
uncontrol high dose ic laba
elig biolog maintain ic laba
elig biolog maintain ic laba
patient thousand
yr
peanut food allergi
also develop peanut allergi compani estim
million adult patient diagnos us expect target
adult risk anaphylact reaction
compani conduct phase studi enrol adult peanut allergi patient
histori anaphylaxi random subject evalu peanut
toler oral baselin day accord practal guidelin
symptom sever baselin day adjud blind independ
subject arm two placebo arm exhibit mild symptom
baselin fit moderate-to-sever definit despit histori anaphylaxi
toler baselin
figur improv peanut toler cumul day
moderate-to-sever baselin subject improv peanut toler
cumul improv symptom sever day pbo subject
versu dose subject present concomit allerg
symptom exploratori endpoint suggest may potenti
address multipl allerg condit consist mechan
expect updat develop plan peanut allergi program
come month indic plan initi placebo-control sc multi-dos phase
trial moderate-to-sever baselin adult peanut allergi await detail trial
physician indic would like see data program
understand potenti highlight possibl util combin
shorter-term desensit approach similarli strategi pursu
aimmun sanofi/regeneron studi dupix improv trajectori
desensit aimmun
howev expert express skeptic prospect util biolog
manag peanut allergi consid high potenti cost assum would
price in-lin biolog use atop dermat asthma around
gross annual also unknown rel reimburs broad adopt
oral food challeng standard practic possibl challeng smaller commun
practic current dont model peanut allergi opportun explicitli
program option reflect part pipeline/platform valu
gpp ppp
could first-in-class agent two orphan dermatolog condit
gener pustular psoriasi gpp palmoplantar pustulosi ppp
current standard care employ off-label agent moderate/sever
patient mix result
target could promis approach indic estim
revenu potenti peak initi efficaci data gpp could becom avail
late
anab second wholli own clinical-stag asset antibodi
indicationsgener pustular psoriasi gpp
normal individu signal balanc function receptor
antagonist dysfunct receptor antagon elev level lead
inflammatori respons may lead erupt pustul wide distribut gpp
palm sole ppp gpp life threaten sever patient
ppp may lead signific pain inabl stand walk work
fda-approv drug treat gpp ppp
believ antibodi potenti manag gpp ppp
block receptor compani estim sever gpp affect
patient us moderate-sever ppp affect patient
figur dysfunct may lead sever inflammatori diseas
phase data suggest inhibitori activ attract pk/pd
compani recent present updat phase data eaaci
congress explor dose rang iv sc sad cohort
mg iv weekli four week mad cohort
compani saw dose-limit toxic sae manag safeti profil
common teae headach upper respiratori tract infect
half-lif day similar iv/sc administr
inhibitori activ observ dose level iv day
figur pharmacokinet
orphan indic develop may offer potenti acceler timelin
initi gpp phase trial first half expect
initi phase ppp trial back half year
given potenti price differenti gpp sever smaller popul
could warrant higher price point ppp less sever off-label treatment
option larger address market expect compani strateg develop
plan influenc market build assumpt follow initi phase dataset
preliminarili model play role indic assum price
posit product uptak ppp strateg decis focu primarili gpp
could allow much higher price point consid ultra-orphan indic
yr
preval patient
gross net
preval patient
gross net
yr
discoveri platform partnership
develop first-in-class antibodi candid area unmet need
inflamm partner addit product
compani antibodi discoveri platform replic vitro natur process
antibodi gener somat hypermut possibl enabl access target
difficult address estim year novel target ind equival
file believ compani pipelin support potenti platform six
antibodi advanc clinic sinc
believ anapti approach develop first-in-class agent high risk-reward
strategi believ find promis indic target high-unmet need remain
key challeng biotech compani elev scarciti valu
 perspect encourag compani earli success believ
signific platform valu compani discoveri engin
figur anaptysbio wholli own partner product pipelin
establish collabor tesaro immune-oncolog celgen
inflamm discoveri earli develop antibodi alreadi
yield upfront/mileston payment elig receiv
mileston development/regulatori mileston
commerci mileston per target tesaro agreement
development/regulatori mileston per target celgen agreement net
sale royalti single-digit partnership program earli
develop see partnership testament anab success track
record develop new antibodi see potenti upsid stock
program eventu approv fda current
on-going registr trial msi-h tumor
arriv target price use blend valuat approach includ
product-bas dcf dcf
dcf model assum discount rate fulli dilut share million
tax rate assign pipelin valu account addit indic
detail dcf compon includ follow
second valuat scenario support target reflect
increas revenu decreas sg
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
adjust account histor probabl success specif diseas
categori standard mind assign follow probabl success
atop slightli lower standard assumpt
asset phase reflect promis efficaci data phase trial
counterweight small sampl size single-dos natur studi
consist standard assumpt reflect
strong biolog rational target indic extrapol
limit single-dos phase studi
slightli higher standard assumpt
phase asset gpp reflect strong biolog rational target
indic ppp consist standard assumpt
cash cash equival expect last
project net cash use oper compani elig
pre-commerci mileston exist partnership clinic
tesaro celgen addit commerci mileston royalti
valuat assum posit readout across multipl
program within next month increas po asthma atop
dermat gpp/ppp greater market share
ad grey valuat assum failur across asthma
gpp/ppp partner io program po lower convict atop
dermat data po reduc pipelin valu
regulatory/clin risk includ limit trial enrol delay poorli
design studi
inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
failur asthma atop dermat asthma studi
failur gpp/ppp studi
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
inabl manufactur suffici quantiti pipelin
candid meet clinic commerci demand
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payor-impos access
access reimburs challeng
price challeng earlier pipelin candid
competit biolog small molecul asthma atop dermat
competit gpp ppp
research develop expens
sell gener administr expens
profit loss tax
net incom particip secur
net incom loss part secur
weight average share use calcul dilut ep
charl martineau univers toronto figur balanc sheet
cash equival
prepaid expens current asset
properti equip net
commit conting
amort debt discount
loss/ dispos fix asset
chang asset liabil
prepaid expens asset
net cash use oper activ
purchas properti equip
sale ppe
purchas invest
sale/matur invest
net cash use invest activ
proce note payabl
proce issuanc debt
proce exercis stock option
payment offer cost
payment debt issuanc cost
payment note payabl stockhold
proce issuanc prefer stock net issuanc cost
proce issuanc common stock net
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
compani mention price
